Showing results (371-380 of 387) with videos related to

Sort By:
Pageof 39
Blood|March 27, 2004
Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantationAngela Dispenzieri, Morie A Gertz, Robert A Kyle, et al.
American Journal of Hematology|October 29, 2017
MYD88 mutation status does not impact overall survival in Waldenström macroglobulinemiaJithma P Abeykoon, Jonas Paludo, Rebecca L King, et al.
American Journal of Hematology|October 23, 2015
Personalized risk prediction for event-free survival at 24 months in patients with diffuse large B-cell lymphomaMatthew J Maurer, Jean-Philippe Jais, Hervé Ghesquières, et al.
Blood|April 21, 2017
Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLLWei Ding, Betsy R LaPlant, Timothy G Call, et al.
Experimental Hematology & Oncology|April 30, 2025
Hypomagnesemia in lymphoma patients receiving CAR T therapy correlates with immune dysfunction and decreased survivalJennifer J Gile, Patrizia Mondello, Zixing Wang, et al.
Blood Advances|February 17, 2022
Clinical activity of single-dose systemic oncolytic VSV virotherapy in patients with relapsed refractory T-cell lymphomaJoselle Cook, Kah-Whye Peng, Thomas E Witzig, et al.
The New England Journal of Medicine|December 12, 2017
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell LymphomaSattva S Neelapu, Frederick L Locke, Nancy L Bartlett, et al.
American Journal of Hematology|December 10, 2019
Impact of MYD88<sup>L265P</sup> mutation status on histological transformation of Waldenström MacroglobulinemiaSaurabh Zanwar, Jithma P Abeykoon, Eric Durot, et al.
Mayo Clinic Proceedings|August 13, 2010
Diagnosis and management of Waldenström macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelinesStephen M Ansell, Robert A Kyle, Craig B Reeder, et al.
American Journal of Hematology|January 13, 2024
The Lymphoma Epidemiology of Outcomes cohort study: Design, baseline characteristics, and early outcomesJames R Cerhan, Matthew J Maurer, Brian K Link, et al.
Pageof 39